Immune checkpoint inhibitors in infectious disease

Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious diseas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunological reviews 2024-09
Hauptverfasser: King, Hannah A D, Lewin, Sharon R
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Immunological reviews
container_volume
creator King, Hannah A D
Lewin, Sharon R
description Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD-1) to induce durable immune-mediated control of HIV, given that anti-PD-1 can restore function to exhausted HIV-specific T cells and also reverse HIV latency, a long-lived form of viral infection. We highlight several key studies and future directions of research in relation to anti-PD-1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment (AIDS, 2018, 32, 1491), maintenance (PLoS Pathog, 2016, 12, e1005761; J Infect Dis, 2017, 215, 911; Cell Rep Med, 2022, 3, 100766) and reversal of HIV latency (Nat Commun, 2019, 10, 814; J Immunol, 2020, 204, 1242), enhancement of HIV-specific T cell function (J Immunol, 2022, 208, 54; iScience, 2023, 26, 108165), and investigating the effects of anti-PD-1 and anti-CTLA-4 in vivo in people with HIV on ART with cancer (Sci Transl Med, 2022, 14, eabl3836; AIDS, 2021, 35, 1631; Clin Infect Dis, 2021, 73, e1973). Our future work will focus on the impact of anti-PD-1 in vivo in people with HIV on ART without cancer and potential combinations of anti-PD-1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.
doi_str_mv 10.1111/imr.13388
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3102075501</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3102075501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c210t-df1f9a41f27d666e57015d4e159b03306f293e95c0393a83c68fc7519480e8623</originalsourceid><addsrcrecordid>eNo9kD1PwzAQhi0EoqUw8AdQRxhS7uzYsUdU8VGpEgtIbFbinFVDkxQ7Gfj3BFo4nXTv8OjV6WHsEmGB49yGJi5QCK2P2BQVQAZKvh2zKSDIjGujJuwspXcALATPT9lEGJ5rlPmU8VXTDC3N3Ybcx64LbT8P7SZUoe9iGuO4nlwfuiHN65CoTHTOTny5TXRxuDP2-nD_snzK1s-Pq-XdOnMcoc9qj96UOXpe1EopkgWgrHNCaSoQApTnRpCRDoQRpRZOae8KiSbXQFpxMWPX-95d7D4HSr1tQnK03ZYtje9YgcChkBJwRG_2qItdSpG83cXQlPHLItgfRXZUZH8VjezVoXaoGqr_yT8n4hv7NF-_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3102075501</pqid></control><display><type>article</type><title>Immune checkpoint inhibitors in infectious disease</title><source>Access via Wiley Online Library</source><creator>King, Hannah A D ; Lewin, Sharon R</creator><creatorcontrib>King, Hannah A D ; Lewin, Sharon R</creatorcontrib><description>Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD-1) to induce durable immune-mediated control of HIV, given that anti-PD-1 can restore function to exhausted HIV-specific T cells and also reverse HIV latency, a long-lived form of viral infection. We highlight several key studies and future directions of research in relation to anti-PD-1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment (AIDS, 2018, 32, 1491), maintenance (PLoS Pathog, 2016, 12, e1005761; J Infect Dis, 2017, 215, 911; Cell Rep Med, 2022, 3, 100766) and reversal of HIV latency (Nat Commun, 2019, 10, 814; J Immunol, 2020, 204, 1242), enhancement of HIV-specific T cell function (J Immunol, 2022, 208, 54; iScience, 2023, 26, 108165), and investigating the effects of anti-PD-1 and anti-CTLA-4 in vivo in people with HIV on ART with cancer (Sci Transl Med, 2022, 14, eabl3836; AIDS, 2021, 35, 1631; Clin Infect Dis, 2021, 73, e1973). Our future work will focus on the impact of anti-PD-1 in vivo in people with HIV on ART without cancer and potential combinations of anti-PD-1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.</description><identifier>ISSN: 0105-2896</identifier><identifier>ISSN: 1600-065X</identifier><identifier>EISSN: 1600-065X</identifier><identifier>DOI: 10.1111/imr.13388</identifier><identifier>PMID: 39248154</identifier><language>eng</language><publisher>England</publisher><ispartof>Immunological reviews, 2024-09</ispartof><rights>2024 The Author(s). Immunological Reviews published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c210t-df1f9a41f27d666e57015d4e159b03306f293e95c0393a83c68fc7519480e8623</cites><orcidid>0000-0002-0330-8241</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39248154$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>King, Hannah A D</creatorcontrib><creatorcontrib>Lewin, Sharon R</creatorcontrib><title>Immune checkpoint inhibitors in infectious disease</title><title>Immunological reviews</title><addtitle>Immunol Rev</addtitle><description>Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD-1) to induce durable immune-mediated control of HIV, given that anti-PD-1 can restore function to exhausted HIV-specific T cells and also reverse HIV latency, a long-lived form of viral infection. We highlight several key studies and future directions of research in relation to anti-PD-1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment (AIDS, 2018, 32, 1491), maintenance (PLoS Pathog, 2016, 12, e1005761; J Infect Dis, 2017, 215, 911; Cell Rep Med, 2022, 3, 100766) and reversal of HIV latency (Nat Commun, 2019, 10, 814; J Immunol, 2020, 204, 1242), enhancement of HIV-specific T cell function (J Immunol, 2022, 208, 54; iScience, 2023, 26, 108165), and investigating the effects of anti-PD-1 and anti-CTLA-4 in vivo in people with HIV on ART with cancer (Sci Transl Med, 2022, 14, eabl3836; AIDS, 2021, 35, 1631; Clin Infect Dis, 2021, 73, e1973). Our future work will focus on the impact of anti-PD-1 in vivo in people with HIV on ART without cancer and potential combinations of anti-PD-1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.</description><issn>0105-2896</issn><issn>1600-065X</issn><issn>1600-065X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kD1PwzAQhi0EoqUw8AdQRxhS7uzYsUdU8VGpEgtIbFbinFVDkxQ7Gfj3BFo4nXTv8OjV6WHsEmGB49yGJi5QCK2P2BQVQAZKvh2zKSDIjGujJuwspXcALATPT9lEGJ5rlPmU8VXTDC3N3Ybcx64LbT8P7SZUoe9iGuO4nlwfuiHN65CoTHTOTny5TXRxuDP2-nD_snzK1s-Pq-XdOnMcoc9qj96UOXpe1EopkgWgrHNCaSoQApTnRpCRDoQRpRZOae8KiSbXQFpxMWPX-95d7D4HSr1tQnK03ZYtje9YgcChkBJwRG_2qItdSpG83cXQlPHLItgfRXZUZH8VjezVoXaoGqr_yT8n4hv7NF-_</recordid><startdate>20240909</startdate><enddate>20240909</enddate><creator>King, Hannah A D</creator><creator>Lewin, Sharon R</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0330-8241</orcidid></search><sort><creationdate>20240909</creationdate><title>Immune checkpoint inhibitors in infectious disease</title><author>King, Hannah A D ; Lewin, Sharon R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c210t-df1f9a41f27d666e57015d4e159b03306f293e95c0393a83c68fc7519480e8623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>King, Hannah A D</creatorcontrib><creatorcontrib>Lewin, Sharon R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Immunological reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>King, Hannah A D</au><au>Lewin, Sharon R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immune checkpoint inhibitors in infectious disease</atitle><jtitle>Immunological reviews</jtitle><addtitle>Immunol Rev</addtitle><date>2024-09-09</date><risdate>2024</risdate><issn>0105-2896</issn><issn>1600-065X</issn><eissn>1600-065X</eissn><abstract>Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD-1) to induce durable immune-mediated control of HIV, given that anti-PD-1 can restore function to exhausted HIV-specific T cells and also reverse HIV latency, a long-lived form of viral infection. We highlight several key studies and future directions of research in relation to anti-PD-1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment (AIDS, 2018, 32, 1491), maintenance (PLoS Pathog, 2016, 12, e1005761; J Infect Dis, 2017, 215, 911; Cell Rep Med, 2022, 3, 100766) and reversal of HIV latency (Nat Commun, 2019, 10, 814; J Immunol, 2020, 204, 1242), enhancement of HIV-specific T cell function (J Immunol, 2022, 208, 54; iScience, 2023, 26, 108165), and investigating the effects of anti-PD-1 and anti-CTLA-4 in vivo in people with HIV on ART with cancer (Sci Transl Med, 2022, 14, eabl3836; AIDS, 2021, 35, 1631; Clin Infect Dis, 2021, 73, e1973). Our future work will focus on the impact of anti-PD-1 in vivo in people with HIV on ART without cancer and potential combinations of anti-PD-1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.</abstract><cop>England</cop><pmid>39248154</pmid><doi>10.1111/imr.13388</doi><orcidid>https://orcid.org/0000-0002-0330-8241</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0105-2896
ispartof Immunological reviews, 2024-09
issn 0105-2896
1600-065X
1600-065X
language eng
recordid cdi_proquest_miscellaneous_3102075501
source Access via Wiley Online Library
title Immune checkpoint inhibitors in infectious disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T04%3A56%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immune%20checkpoint%20inhibitors%20in%20infectious%20disease&rft.jtitle=Immunological%20reviews&rft.au=King,%20Hannah%20A%20D&rft.date=2024-09-09&rft.issn=0105-2896&rft.eissn=1600-065X&rft_id=info:doi/10.1111/imr.13388&rft_dat=%3Cproquest_cross%3E3102075501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3102075501&rft_id=info:pmid/39248154&rfr_iscdi=true